FINWIRES · TerminalLIVE
FINWIRES

$BIO

7 stories mentioning BIO

Every FINWIRES story that references BIO, newest first.

Research

Research Alert: CFRA Maintains Sell Rating On Shares Of Bio-rad Laboratories Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raised our 12-month target price by $10 to $245, reflecting a 27x multiple on our 2026 EPS estimate, a discount to BIO's three-year historical forward average of 29.5x. We lowered our 2026 EPS estimate to $9.09 from $9.17 and 2027 to $9.80 from $9.87. Though valuations improved somewhat following recent reports of a meaningful stake by activist investor Elliott Management, we think BIO and life sciences tools and services peers continue to navigate a difficult operating environment with pressures in key end markets such as biotech and government/academia. Following BIO's guidance during the Q1 earnings report, we anticipate flat to negative 0.5% sales growth in 2026, along with adjusted operating margin compression to 10.6% from 12.1%. BIO had total cash of $1.6B as of March 31, 2026, supporting the company's negative net debt position (cash exceeds debt).

$BIO
Research

Research Alert: Bio-rad Laboratories Rallies On Wsj Report Of Elliott Management Stake

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares rallied on a WSJ report that activist firm Elliott Management owns a meaningful stake in BIO, though the specific ownership level remains undisclosed. Elliott has made multiple high-profile U.S. health care investments, including Medtronic, Charles River Laboratories, DexCom, and Catalent. The activist firm also holds a stake in German health care firm Sartorius, of which BIO owns 38% of outstanding common shares. We recently downgraded our view on BIO to Sell from Hold. The company reduced revenue and margin expectations during Q1 2026 earnings due to headwinds from the ongoing U.S.-Iran conflict, including weaker diagnostics sales and higher freight costs. We think the near-term operating environment for BIO and peers remains highly challenging, with ongoing weakness in key end markets such as academia and smaller biotech continuing to pressure performance.

$BIO
Research

Research Alert: Bio-rad Laboratories Rallies On Wsj Report Of Elliott Management Stake

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares rallied on a WSJ report that activist firm Elliott Management owns a meaningful stake in BIO, though the specific ownership level remains undisclosed. Elliott has made multiple high-profile U.S. health care investments, including Medtronic, Charles River Laboratories, DexCom, and Catalent. The activist firm also holds a stake in German health care firm Sartorius, of which BIO owns 38% of outstanding common shares. We recently downgraded our view on BIO to Sell from Hold. The company reduced revenue and margin expectations during Q1 2026 earnings due to headwinds from the ongoing U.S.-Iran conflict, including weaker diagnostics sales and higher freight costs. We think the near-term operating environment for BIO and peers remains highly challenging, with ongoing weakness in key end markets such as academia and smaller biotech continuing to pressure performance.

$BIO
Sectors

Sector Update: Healthcare Stocks Decline Pre-Bell Monday

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) 0.6% lower.Regeneron Pharmaceuticals (REGN) stock was down more than 11% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.Bio-Rad Laboratories (BIO) has attracted a sizable investment from Elliott Investment Management, which plans to push the life-science tools supplier to improve its lagging stock performance, The Wall Street Journal reported, citing people familiar with the matter. Bio-Rad Laboratories shares were up more than 7% premarket.Boston Scientific (BSX) entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its previously announced $5 billion share buyback authorization, the company said. Boston Scientific also said it invested $1.5 billion for an approximately 34% stake in privately held MiRus. Shares of Boston Scientific were up about 2% pre-bell.

$BIO$BSX$IBB$JPM$REGN$XLV
Wire

Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says

Bio-Rad Laboratories' (BIO) sales growth should recover in 2027 following idiosyncratic product headwinds, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's new management will make efforts to structurally improve its margin profile.RBC said that some of the challenges Bio-Rad faces are company-specific, noting, for instance, that demand for Bio-Rad's process chromatography products is negatively impacted this year by the US Center for Disease Control's revisions of the childhood and adolescent immunization schedule.Analysts said that the company's near-term earnings before interest and taxes, or EBIT, margin growth target in the mid-teens, up from the 11% guidance for 2026, strongly signals meaningful restructuring ahead.RBC resumed coverage on the stock with an outperform rating and a $320 price target.Price: $248.61, Change: $+2.34, Percent Change: +0.95%

$BIO
Research

Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.

$BIO
Research

Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.

$BIO